AI-Powered Wearables Move Closer to Clinical Use: FDA Clears New Arrhythmia Model

November 14, 2026
Laatste bedrijfsnieuws over AI-Powered Wearables Move Closer to Clinical Use: FDA Clears New Arrhythmia Model

November 14, 2026 — Wearable heart-monitoring devices are quietly shifting from consumer fitness trackers into clinically reviewed tools, as regulators clear AI analysis software and investors back new cardiac patch companies.

PulseAI Wins 510(k) for Wearable Arrhythmia Analysis

Belfast medtech firm PulseAI has received U.S. FDA 510(k) clearance for its AI arrhythmia analysis model designed to work with wearables. Recordings are uploaded for cloud-based analysis, and a structured result is returned to the connected app for clinician review.

In a 296-participant prospective study published in Heart Rhythm, the company says its algorithm improved AFib detection sensitivity and cut inconclusive readings by 92% compared with the native watch algorithm. The clearance matters because it signals FDA acceptance of AI as a second-layer analysis tool on top of consumer-grade ECG hardware.

Cardiac Patch Startup Skribe Raises USD 1.6 Million

U.S. startup Skribe closed a USD 1.6 million seed round led by SeaX, with GoAhead Ventures and Marin Sonoma Impact Ventures joining. Its Aurora system pairs a multi-sensor adhesive patch with AI software to estimate left ventricular ejection fraction — a measure of how well the heart pumps. Home-based monitoring is the longer-term target, and the system was picked for the FDA's READI-Home Innovation Challenge.

Market: AI Wearable Monitoring Still Growing Fast

A report from Expert Market Research puts the AI wearable health monitoring market at USD 2.80 billion in 2025, projected to reach USD 18.22 billion by 2035, a 20.60% CAGR. Demand is driven by rising AFib, hypertension and sleep apnea cases, wider adoption of smartwatches, rings and patches, and clearer regulatory paths for wearable rhythm devices.

Regulation: More Wearables Enter Class II

The FDA also finalized Class II special-control classifications for a wearable vibration device for orthopedic use and an external mechanical stimulator for congestion relief, giving manufacturers a defined approval route rather than automatic Class III assignment.

What it means for suppliers

The direction is fairly consistent: more devices will record vitals at home, send them through an AI layer, and return a result a clinician can check. That keeps demand steady for reliable sensing hardware — pulse oximeters, ECG sensors, blood pressure and temperature modules, and the accessories that go with them.

SaferLife Products Co., Ltd. supplies pulse oximeters, patient monitors and vital-signs accessories to distributors worldwide.